EXAGEN INC.(XGN)Stock Analysis
AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →13F Pro Quality Score
Rank #2,588 of 2,962 stocks
Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Nov 14, 2026.
Revenue Growth
Profitability
Balance Sheet
Earnings Quality
Free Cash Flow
Institutional Flow
Revenue Scale
Dilution Risk
XGN Stock Analysis & AI Quality Score
Data updated 2026-09-11AI stock analysis and institutional research for EXAGEN INC. (XGN), a Healthcare sector company. 13F Pro's AI-powered ranking engine scores XGN at 27.3/100 on a 32-signal composite quality model, placing it at rank #2,588 of 2,962 stocks — the bottom half of the AI-ranked universe. Areas of concern include institutional flow (5.9) and balance sheet strength (6.6), which score below median versus the broader universe. Shareholder dilution risk is elevated at 30.8/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q2 2026), EXAGEN INC. reports quarterly revenue of $19.9M, net income of $-3.2M, free cash flow of $3.4M. Top institutional holders of XGN by reported 13-F value include WEXFORD CAPITAL, NANO CAP NEW MILLENNIUM GROWTH FUND L P, VANGUARD CAPITAL MANAGEMENT, based on the most recent SEC filings. XGN trades on the Nasdaq exchange and files with the SEC under CIK 1274737. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate XGN daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for EXAGEN INC. directly from SEC EDGAR. EXAGEN INC.'s 13F Pro composite quality score has ranged between 14 and 31 since 2021, currently 27.3 — an improving long-term trajectory across 68 quarterly and live scoring snapshots.
Revenue
Q2 2026
$19.9M
Net Income
Q2 2026
$-3.2M
Free Cash Flow
Q2 2026
$3.4M
ROIC
Q2 2026
-19.4%
D/E Ratio
Q2 2026
1.91
Revenue & Net Income
Earnings Per Share
Key Financials Over Time
Export Financial Table · ProRevenue
+19.7% YoYNet Income
-32.0% YoYOperating Income
-3.2% YoYEPS (Diluted)
-12.0% YoYTotal Assets
+29.8% YoYTotal Debt
+13.9% YoYOp. Cash Flow
-2.6% YoYFree Cash Flow
-3.4% YoY| Metric | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Revenue | $66.6M +19.7% | $55.6M +5.9% | $52.5M +15.3% | $45.6M -5.7% | $48.3M +15.1% | $42.0M |
| Net Income | $-20.0M -32.0% | $-15.1M +36.2% | $-23.7M +50.0% | $-47.4M -76.5% | $-26.9M -60.9% | $-16.7M |
| Operating Income | $-14.1M -3.2% | $-13.6M +40.3% | $-22.8M +50.4% | $-46.1M -91.3% | $-24.1M -58.5% | $-15.2M |
| EPS (Diluted) | $-0.93 -12.0% | $-0.83 +38.1% | $-1.34 +51.6% | $-2.77 -64.9% | $-1.68 -27.3% | $-1.32 |
| Total Assets | $58.0M +29.8% | $44.7M -21.5% | $56.9M -34.0% | $86.2M -30.2% | $123.4M +57.5% | $78.4M |
| Total Debt | $23.6M +13.9% | $20.7M +4.6% | $19.8M -32.2% | $29.2M +6.1% | $27.5M +3.1% | $26.7M |
| Operating Cash Flow | $-13.6M -2.6% | $-13.3M +8.2% | $-14.5M +55.0% | $-32.1M -58.6% | $-20.3M -43.9% | $-14.1M |
| Free Cash Flow | $-14.3M -3.4% | $-13.8M +9.8% | $-15.3M +58.1% | $-36.5M -61.1% | $-22.6M -55.7% | $-14.5M |
Get alerted when XGN's score changes
Free account: watchlist tracking, the daily AI brief, and the AI screener.
Available Research
13F Pro tracks comprehensive data for EXAGEN INC. including:
Top Institutional Holders of XGN
WEXFORD CAPITAL LP
$3.7M792,855 shNANO CAP NEW MILLENNIUM GROWTH FUND L P
$3.1M675,000 shVANGUARD CAPITAL MANAGEMENT LLC
$2.8M612,832 shFourWorld Capital Management LLC
$2.8M596,528 shSILVERCREST ASSET MANAGEMENT GROUP LLC
$2.4M514,761 shKENNEDY CAPITAL MANAGEMENT LLC
$2.3M485,048 shMink Brook Asset Management LLC
$2.2M475,944 shJANE STREET GROUP, LLC
$1.5M322,502 shACADIAN ASSET MANAGEMENT LLC
$1.4M310,084 shFirst Eagle Investment Management, LLC
$1.4M306,965 sh
| Fund | Value | Shares |
|---|---|---|
| WEXFORD CAPITAL LP | $3.7M | 792,855 |
| NANO CAP NEW MILLENNIUM GROWTH FUND L P | $3.1M | 675,000 |
| VANGUARD CAPITAL MANAGEMENT LLC | $2.8M | 612,832 |
| FourWorld Capital Management LLC | $2.8M | 596,528 |
| SILVERCREST ASSET MANAGEMENT GROUP LLC | $2.4M | 514,761 |
| KENNEDY CAPITAL MANAGEMENT LLC | $2.3M | 485,048 |
| Mink Brook Asset Management LLC | $2.2M | 475,944 |
| JANE STREET GROUP, LLC | $1.5M | 322,502 |
| ACADIAN ASSET MANAGEMENT LLC | $1.4M | 310,084 |
| First Eagle Investment Management, LLC | $1.4M | 306,965 |
Companies Similar to XGN
Ranked by quality-profile closeness and shared hedge-fund ownership — not just sector membership.
electroCore, Inc.
NATURAL ALTERNATIVES INTERNATIONAL INC
Neuronetics, Inc.
BIODESIX INC
Pulmonx Corp
CUMBERLAND PHARMACEUTICALS INC
Starling Oncology, Inc.
NeuroPace Inc
Similarity is computed from the 8 composite sub-scores and latest-quarter 13F conviction holdings (index-style filers excluded). Refreshed monthly.
More Healthcare Companies
View all Healthcare →Put XGN on your watchlist
Track score changes the day EXAGEN INC. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.
Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).
Popular Research
Is XGN a good stock to buy?
13F Pro's AI-powered analysis of EXAGEN INC. (XGN) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for XGN are available on the XGN stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing. XGN is classified as a small company.
Which hedge funds own XGN?
Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling XGN. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of EXAGEN INC.'s investment landscape.